Post‐intestine transplant graft‐versus‐host disease: Associated with inclusion of a liver graft and with a high mortality risk by Clouse, Jared W. et al.
A
cc
ep
te
d 
A
rt
ic
le
MR. JARED  CLOUSE (Orcid ID : 0000-0001-5320-8671) 
DR. SHEKHAR AVINASH  KUBAL (Orcid ID : 0000-0003-4043-2943) 
DR. JONATHAN A FRIDELL (Orcid ID : 0000-0002-8708-1506) 
DR. RICHARD S MANGUS (Orcid ID : 0000-0003-4300-2594) 
 
Article type   : Original Article 
 
Post-intestine transplant graft-versus-host disease: Associated with inclusion of a liver 
graft and with a high mortality risk 
 
Jared W. Clouse, Chandrashekhar A. Kubal, Jonathan A. Fridell, 
E. Jordan Pearsall, Richard S. Mangus
 
From the Department of Surgery, Transplant Division, Indiana University School of 
Medicine, Indianapolis, Indiana, USA 
 
* This paper was presented at the 2017 American Transplant Congress and at the 2017
meetings of the Intestine Rehabilitation and Transplantation Association
 
 
 
Running head: GVHD in intestine transplantation 
Key words: Intestine transplant, multivisceral transplant, graft-versus-host disease, 
complications, outcomes 
Corresponding author contact information: 
Dr. Richard S. Mangus, MD MS FACS 
Director of Intestine Transplant Program 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Clouse, J. W., Kubal, C. A., Fridell, J. A., Pearsall, E. J., & Mangus, R. S. (2018). Post-intestine transplant graft-versus-host 
disease: Associated with inclusion of a liver graft and with a high mortality risk. Clinical Transplantation, 0(ja), e13409. 
https://doi.org/10.1111/ctr.13409
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Transplant Division, Department of Surgery, Indiana University School of Medicine 
550 N University Blvd, Room 4601, Indianapolis, Indiana 46202-5250 
Phone: (317) 944-4370 Fax: (317) 948-3268   E-mail: rmangus@iupui.edu 
 
Author contributions: 
Jared W. Clouse, MS 
Participated in data collection, analysis of data, and drafting of the manuscript. No funding. 
No conflict of interest. 
Chandrashekhar A Kubal, MD PhD 
Participated in patient care and critical review of the manuscript. No funding. No conflict of 
interest. 
Jonathan A Fridell, MD 
Participated in patient care and critical review of the manuscript. No funding. No conflict of 
interest. 
E. Jordan Pearsall, BSN 
Participated in data collection, analysis of data, and critical review of the manuscript. No 
funding. No conflict of interest. 
Richard S Mangus, MD 
Participated in research design, performance of research, data analysis, and writing of the 
paper.  
Funding: No outside funding.  
Conflict: F. Kohler-Chemie (Germany) provides travel support and honoraria.  
 
Abbreviations: 
ANOVA  Analysis of variance 
IBM  International Business Machines 
IT  Intestine transplant 
GVHD  Graft-versus-host disease 
HSC  Hematopoietic stem cell 
MELD  Model for end-stage liver disease score 
MMVT Modified multivisceral transplant 
MVT  Multivisceral transplant 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
rATG  Rabbit antithymocyte globulin 
SPSS   Statistical package for the social sciences 
 
Abstract 
Introduction 
This study reports the incidence, anatomic location, and outcomes of graft-versus-host 
disease (GVHD) at a single active intestine transplant center.  
 
Methods 
Records were reviewed for all patients receiving an intestine transplant from 2003 to 2015. 
Pathology reports and pharmacy records were reviewed to establish the diagnosis, location, 
and therapeutic interventions for GVHD.  
 
Results 
A total of 236 intestine transplants were performed during the study period, with 37 patients 
(16%) developing GVHD. The median time to onset of disease was 83 days, with 89% of 
affected patients diagnosed in the first year post-transplant. Mortality for affected patients 
was 54% in the one-year after GVHD diagnosis. 
 
Skin lesions were the most common manifestation of GVHD. Other sites of disease included 
lungs, bone marrow, oral mucosa, large intestine, and brain. The incidence of GVHD was 
16% in adult patients, and slightly lower in pediatric recipients (13%). In adults, increasing 
graft volume (isolated versus multi-organ) and liver inclusion were associated with increasing 
risk of GVHD, though this was not seen in pediatric patients. 
 
Conclusion 
Overall, 16% of intestine transplant recipients developed GVHD. GVHD is associated with 
high mortality, and disease in the lungs, brain, and bone marrow was universally fatal.  
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Introduction 
Intestine transplant is a potentially life-saving procedure for patients who have 
experienced intestine failure, unresectable mesenteric tumors, portomesenteric thrombosis, 
among other intraabdominal pathologies. Although advances have occurred, intestine 
transplant continuous to be replete with risk of morbidity and mortality. Serious post-
transplant complications commonly arise limiting the efficacy of the intestine graft as well as 
the long-term survival of many transplant recipients.  
Graft-versus-host disease (GVHD) is a serious and potentially life-threatening 
complication arising in intestine, other solid organ, and allogenic hematopoietic stem cell 
(HSC) transplantation. GVHD occurs when T-cells from the donor tissue are activated by 
host antigen-presenting cells causing donor lymphocytes to initiate an immune response 
against recipient tissue. All host tissues are susceptible to attack by activated donor cells but 
the skin, liver, and gastrointestinal tract are the most common sites of disease.[1] The 
incidence of GVHD in HSC transplantation is high and has been shown to be 50% in some 
studies.[2]  
In solid organ transplantation, the incidence of GVHD is much lower, but varies 
greatly by type of organ transplanted. Small intestine transplants, whether as a multivisceral 
graft or as an isolated intestine graft, have the highest incidence of GVHD in solid organ 
transplantation with disease being seen in over 20% of small bowel recipients.[3, 4] In 
contrast, GVHD develops in only 1-2% of liver transplant recipients, and only a few case 
reports of GVHD after kidney transplantation have been reported.[5-7] Although the 
incidence of GVHD in solid organ transplantation is low, the development of disease can 
have catastrophic consequences with over 75% mortality associated with GVHD in liver 
transplant recipients.[5] Clinical predictors of GVHD are not well identified. The size of the 
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transplant graft relative to the recipient may have an association simply because of the greater 
volume of transplanted tissue. Alternatively, immunologically active organs such as the liver, 
intestine and lung may be more likely to attack host tissue as these organs routinely surveil 
the body for foreign antigens and have a greater capacity to mount an independent 
immunologic response. 
The present study reports the incidence, anatomic location, and outcomes for GVHD 
in intestine transplant patients at a single center. Subgroup analysis is performed in an 
attempt to identify those patients at risk for the development of GVHD in this high-risk 
population. 
 
Methods 
 Medical records for all patients receiving an intestine transplant at a single center 
from 2003 to 2015 were retrospectively reviewed. Patients received an isolated intestine 
transplant (IT) or an intestine transplant en bloc with other organs as a multivisceral 
transplant (MVT; liver, stomach, pancreas, small intestine) or modified multivisceral 
transplant (MMVT; stomach, pancreas, small intestine). A subset of patients also received a 
donor large intestine as part of a small intestine transplant. All patients receiving an intestine 
allograft were included regardless of transplant type, large intestine inclusion, or outcome.  
 Graft-versus-host disease was diagnosed based on clinical indications and 
histopathologic evidence using biopsies from affected areas (skin, bone marrow, lungs). All 
patients with an unexplained skin rash in the post-transplant period underwent skin biopsy to 
determine if the rash represented GVHD. In all cases, the dermatopathologists were able to 
conclusively determine if the rash represented GVHD, versus some other etiology. Diagnosis 
of GVHD in the lung and bone marrow also required tissue biopsy. Open biopsy of the lung 
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in an already compromised patient is a challenging clinical decision, and we only pursued 
lung biopsy in those patients with a compromised pulmonary status for whom all other 
etiologies had been excluded. Bone marrow biopsy was more easily obtained, but generally 
just demonstrated a marrow devoid a cellular components. No liver biopsies were taken to 
assess for GVHD in patients with a liver exclusive graft, therefore no GVHD of the liver is 
noted. Additionally, a single case of GVHD in the central nervous system was diagnosed via 
a computed tomography (CT) scan. The CT scan showed demyelination of the brainstem, 
periventricular white matter, and cerebellar hemispheres bilaterally which is consistent with 
GVHD in the CNS. Pharmacy records were reviewed in documented cases to assess 
therapeutic interventions and to confirm therapy administration for the diagnosis of GVHD. 
At this center, treatment of GVHD consisted of a steroid taper only, and no other therapy was 
employed. Cutaneous GVHD was graded (I-IV) according to consensus criteria.[8]  
 Intestine and multivisceral transplant procedures performed at our center have been 
previously described.[9-11] Intestine decontamination was never administered to the donor or 
to the recipient as part of intestine transplant process.[12] When another center was procuring 
the donor pancreas, the duodenum was stapled prior to use of intestine decontamination to 
prevent exposure of the isolated intestine graft to the decontamination solution.[13] Similar 
immunosuppression induction therapy was given to each patient and consisted of 3-5 
alternating doses of solumedrol (500, 250, 125mg) and rabbit antithymocyte globulin (rATG, 
total dose 5-6mg/kg) with a single dose of rituximab (150mg/m2). Tacrolimus (goal level 
10ng/dL (early) and 7-8ng/dL (later)) and low dose steroids were used for 
immunosuppression maintenance.[14] Second agents such as rapamycin, mycophenolate and 
azathioprine were almost never used in this patient cohort. Infection prophylaxis with broad-
spectrum antibiotics was continued for 48 hours post-operatively in most cases, and up to one 
week post-transplant in cases with significant intraoperative contamination. 
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Immunosuppression surveillance using cell counts (e.g. CD3) or commercially available 
markers (e.g. ImmuKnow) was not routinely performed. 
Patients were stratified into groups based on age (adults and pediatric) and transplant 
type (IT, MMVT, MVT) for data analysis. Post-GVHD survival outcomes were measured 
from the day of GVHD diagnosis, not from the day of transplant. Subgroup analysis was 
performed to determine the impact of donor to recipient size ratio, to determine if a size 
disparity increased the risk of GVHD. The mean of the ratio of donor to recipient height, 
weight, and BMI of affected and non-affected patient groups was utilized. Data were 
analyzed using the software Statistical Package for the Social Sciences (IBM SPSS Statistics 
24, IBM Corporation, Armonk, New York, USA). The institutional review board at Indiana 
University School of Medicine reviewed and approved the retrospective analysis of data from 
the transplant database.  
Results 
Altogether, 236 intestine transplants were performed on 214 patients, with 21 patients 
undergoing multiple intestine transplant procedures. The median age of transplant recipients 
was 42 years, with 184 adult patients (>18 years) and 52 pediatric patients (≤18 years). 
Intestine failure was the primary indication for transplantation in the majority of cases (63%). 
Portomesenteric thrombosis and non-resectable tumors were the other conditions most 
commonly necessitating intestine transplant. The majority of patients (62%) received a MVT, 
while 26% received an IT, and 12% a MMVT. No pediatric patient received a MMVT. 
Donors had a median age of 18 years, and trauma was the primary cause of death. [Table 1] 
The rate of GHVD in this cohort of patients was 16%. The incidence of GVHD in 
MVT was significantly higher (20%) than that seen in MMVT (14%) and IT (7%) (p=0.05). 
In adult patients, a similar pattern was observed with 22% of MVT, 14% of MMVT, and only 
4% of IT patients developing GVHD (p=0.02). In the pediatric population, the overall 
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incidence was slightly lower (13%) with only a slight difference in the rate between MVT 
and IT recipients (15% vs. 11%). [Table 2] Overall, the median time post-transplant to the 
development of GVHD in affected patients was 83 days (62 days in pediatrics and 90 days in 
adults), with 57% of patients diagnosed in the first 90-days post-transplant and 89% within 
the first year. All affected patients were treated with a long steroid taper until the skin lesions 
disappeared. With a short course of therapy, the skin lesions often returned. However, in all 
cases, the lesions did eventually disappear, though a taper of many months duration was 
required. 
 A total of six different pediatric patients developed seven cases of GVHD, with one 
patient developing GVHD after each of their two transplants. Most of the pediatric patients 
were male (72%) and the majority received a MVT graft (72%). All of the affected pediatric 
patients had cutaneous manifestations of GVHD, and only one child developed 
extracutaneous disease, which was found in the lung. All but one pediatric patient (86%) 
developed disease in the first 90 days post-transplant. Only one (17%) child died from the 
direct effects of GVHD, and two (33%) died within the first year post-diagnosis. [Table 3] It 
is unclear whether other deaths, most commonly resulting from infection and sepsis, were 
related to GVHD or its treatment (a prolonged course of moderate dose steroids). 
 GVHD occurred in 29 different adult patients, with one patient having the disease 
twice after two separate transplant procedures. Among adult GVHD patients, 80% had 
received an MVT (n=24), 13% MMVT (n=4) and 7% IT (n=2). There was an even gender 
distribution. The skin was affected in all but one adult patient, while 10 patients developed 
extracutaneous manifestations of disease in the bone marrow, lung, gastrointestinal tract, or 
central nervous system. GVHD manifested itself within the first 90 days post-transplant in 
50% of affected adult patients. Ninety percent of affected adult patients had evidence of 
disease within the first year. There were 41% of affected adult patients alive one year after 
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initial diagnosis of GVHD, but only three adult patients had GVHD as the primary cause of 
death. The one-year survival (post-diagnosis) of adult patients with GVHD in the bone 
marrow, lungs and CNS was even lower (25% (2/8)), and none of these patients was alive at 
2 years post-diagnosis. [Table 3] 
 This study finds an increasing graft volume being associated with a higher risk of 
GVHD. Therefore, an analysis was performed to analyze the ratio of donor to recipient 
height, weight, and BMI. When comparing these ratios in GVHD and non-GVHD groups the 
ratios ranged from 0.99 to 1.01, and there was no significant difference between the groups. 
These data provide evidence that donor to recipient size ratio is not predictive of a diagnosis 
of GVHD. [Table 4] Alternatively, all liver inclusive grafts also had higher graft volume. 
Subgroup analysis of patients that did and did not receive a liver demonstrated a significantly 
higher rate of liver inclusion in the GVHD group (78% (GVHD) versus 59% (no GVHD), 
p=0.02), strongly suggesting an independent mechanism for involvement of the liver in this 
process. Immunologic assessment is also included in Table 4. Panel reactive antibody (PRA), 
T-cell and B-cell crossmatch, and any formation of donor specific antibody (DSA) were not 
associated with increased risk of GVHD. Patients with a lower human leukocyte antigen 
(HLA) mismatch number had a lower risk of GVHD (4 versus 5, p=0.06). Patients who had 
experienced any graft rejection were at lower risk for GVHD (14% (GVHD) versus 36% (no 
GVHD), p<0.01).  
 
Discussion 
 This study reports the incidence, location, and outcomes of GVHD in a large patient 
population undergoing intestine transplantation at a single center. The incidence among this 
cohort was 16% which is congruent with previously published data that show GVHD to range 
from 6% to 29%.[3, 15] The median time to GVHD diagnosis was 83 days, with only four 
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cases being diagnosed after one-year post-transplant. This suggests that some level of graft-
recipient tolerance may develop over time, or that those who are affected have a poor 
immunologic match and die early within their post-transplant course. Among the 35 patients 
who developed graft versus host disease, two developed the disease twice, once after their 
original transplant and again after the subsequent transplant. This suggests that there may be 
a genetic or immunologic factor that predisposes affected patients to develop GVHD. 
Similar to previously published data, the incidence of GVHD in this patient 
population increased as the size of the graft increased (IT to MMVT to MVT).[15-17] This 
increase has been speculated to be from an increase in the amount of lymphoid tissue 
transplanted, but a definitive mechanism has yet to be elucidated.[17] In response to this 
observation, the present study tested the hypothesis that the ratio of donor to recipient size 
would be greater than 1.00 in patients who develop GVHD. In theory, as donor size increased 
in relation to recipient size the volume of immunologically active cells transplanted would be 
proportionally larger, perhaps leading to an increase in the incidence of GVHD. This 
hypothesis was not supported by the data as the ratios of height, weight and BMI in all the 
groups tested varied little from 1.00. Thus, the ratio of donor to recipient height, weight, and 
BMI does not appear to be an important risk factor for the prediction of GVHD development. 
A more promising finding was that liver inclusion was associate with higher risk of GVHD 
(p=0.02). The liver is known to be very immunologically active and may mediate this process 
in these patients. However, GVHD in liver transplant only patients is quite rare, providing 
evidence against this idea. Further work is needed to identify reliable predictors for the 
development of GVHD. Also, additional research is required to elucidate the underlying 
cause of the increase in GVHD incidence among MVT recipients when compared to IT 
recipients, especially if the liver is involved. 
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Other variables not analyzed in this paper that may influence the development of 
GVHD include splenectomy and the use of rATG. Splenectomy has been associated with the 
development of GVHD in HSC transplantation, but in intestine transplantation, results from 
previously published reports are conflicting.[15, 16, 18] Previous reports have shown that the 
use of rATG decreases the incidence of GVHD in reduced-intensity stem cell transplantation 
and may have a similar effect in intestine transplantation.[19, 20] rATG may have similar 
effects on incidence of GVHD in this cohort, but this is impossible to determine without a 
comparison group as all patients in this cohort did receive rATG. 
As previously noted from existing publications, GVHD in solid-organ transplantation 
is associated with high post-transplant mortality.[5] A similar trend is observed in intestine 
transplantation, with 77% of patients dying within the follow-up period, with a median time 
to death of 12.6 months post diagnosis of GVHD.[16] High mortality was also observed in 
the patient population from the present study, with 54% of patients dying during the first year 
after diagnosis (19 of 35). While only four of these deaths were directly attributed to GVHD, 
increased immunosuppression to treat GVHD may have contributed to others. Besides the 4 
patients who died from GVHD, there were 10 more who died of infection (sepsis) within 90 
days of receiving a steroid taper as treatment for GVHD. The argument can be made, then, 
that 14 of 19 deaths were related to GVHD (74%), though this cannot be definitively proven. 
The high mortality among this vulnerable population highlights the need for novel treatment 
options for GVHD.  
Currently, there is no consensus on the best therapy to reverse GVHD, and treatment 
options are lacking in effectiveness. Described treatment options consist of increasing 
immunosuppression, whether through a steroid taper, anti-lymphocytic drugs, anti-
interleukin-2 antibodies, or other biologic therapies.[21, 22]  Cell based treatments are now 
being studied, but none have gained widespread use. Mesenchymal stem cell therapy has 
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been described as GVHD prophylaxis, and was effective in a small patient cohort.[23] 
Extracorporeal photophoresis has also been reported as therapy for GVHD, but this was 
reported to be ineffective.[3] Novel therapies targeting Jak-1/Jak-2 such as ruxolitinib have 
shown promise in treating acute and steroid-resistant GVHD, potentially offering another 
treatment option for patients who suffer from this complication.[24] 
In conclusion, graft-versus-host disease is a serious and potentially life-threatening 
complication occurring after HSC and solid-organ transplantation. Currently, there are few 
effective treatment options, and further work is required to develop to effect therapies. 
Results from this study suggest that GVHD in the intestine transplant population is more 
likely to be seen in patients receiving a liver graft, those with a worse HLA match and 
patients who have not experienced any rejection. Donor-recipient size discordance does not 
appear to predict GVHD in this population. GVHD is associated with high mortality in a 
patient population known to have poor long-term survival.  
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Table 1. Demographics for 236 consecutive intestine transplant patients. 
    
  
Overall Adult Pediatric 
Number 236 (100%) 184 (78%) 52 (22%) 
 
   Recipients   
    
Age (years, median, 
range) 42 50 (19 - 67) 1.6 (0.3 - 18) 
Gender: male 50% 47% 60% 
Race: White 83% 89% 65% 
 
   Disease 
 
  Portomesenteric 
thrombosis 24% 30% 6% 
Tumor 13% 16% 2% 
Intestine failure / Other 63% 54% 92% 
 
   Transplant type 
 
  Intestine only 26% 24% 35% 
Modified multivisceral 12% 15% 0% 
Full multivisceral 62% 61% 65% 
 
   Donors 
      
Age (year, median, 
range) 18 19 (4 - 50) 1.5 (0.1 - 22) 
Gender: male 56% 59% 46% 
Race: White 71% 75% 57% 
 
   Cause of death 
 
  Stroke 12% 13% 12% 
Trauma 59% 62% 46% 
Anoxic brain injury 29% 25% 42% 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
  
Table 2. Incidence of GVHD by age and transplant type       
    
  
No. of 
Patients 
Overall 
Isolated 
Intestine 
Modified 
Multivisceral 
Multivisceral p-value 
Combined 236 16% 7% 14% 20% 0.05 
       
Pediatric 52 13% 11% - 15% 0.72 
       
Adult 184 16% 4% 14% 22% 0.02 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3. Characteristics of 37 patients who developed GVHD. 
 
   
Patient Gender 
Transplant  
Type 
Skin 
Grade 
Other 
Location 
Days to Diagnosis 
Post-transplant 
Outcome 
Cause of 
Death 
Pediatric               
1 Female MVT II - 61 Died, day 123 Pseudoostruction, adenovirus 
2 Male MVT Unknown Lung 67 Died, day 237 GVHD Lung 
3 Male Intestine only II - 55 Alive, day 2499 - 
4 Male Intestine only II - 85 Died, day 594 Liver failure, chronic rejection 
5 Male MVT II - 35 Died, day 475 Liver failure, chronic rejection 
6 Female MVT II - 800 Alive, day 631 - 
7 Male MVT II - 62 Alive, day 358 - 
Adult               
8 Male MMVT II - 28 Died, day 379 CMV disease 
9 Male MVT II - 45 Died, day 93 Fungal sepsis 
10 Male MVT II - 495 Died, day 171 Myocardial infarction 
11 Male MVT II Bone Marrow 122 Died, day 134 GVHD of bone marrow 
12 Female MVT II - 27 Died, day 17 Sepsis, enterobacter 
13 Male MVT II - 29 Died, day 7 Sepsis; fungal, VRE 
14 Male MVT II - 108 Died, day 312 Sepsis 
15 Male MMVT II Lung 34 Died, day 225 Sepsis; pneumonia 
16 Female MVT II Oral Mucosa 217 Died, day 369 Renal Failure 
17 Female MVT II - 22 Died, day 1580 Chronic aspiration, sepsis 
18 Female MVT II - 27 Died, day 233 GVHD 
19 Female MVT II Bone Marrow 350 Died, day 613 Acute myeloid leukemia 
20 Male MVT III Colon 128 Died, day 472 HCV Treatment; sepsis 
21 Male MVT - Bone Marrow 32 Died, day 263 Sepsis; malnutrition 
22 Male MVT II - 87 Alive, day 2031 - 
23 Male MVT II Lung 125 Died, day 401 Pancytopenia, sepsis 
24 Male MVT Unknown - 121 Alive, day 1668 - 
25 Female MVT II - 59 Died, day 1369 Sarcoma in liver 
26 Female MMVT II Bone Marrow 92 Died, day 29 Chronic fungal sepsis 
27 Female Intestine Only Unknown - 419 Died, day 99 HSV infection 
28 Male MVT III-IV CNS, Oral 
Mucosa 
32 Died, day 216 Hemorrhagic stroke 
29 Male MVT II - 41 Alive, day 1097 - 
30 Female MVT II - 167 Died, day 313 Sepsis 
31 Female MVT II - 177 Died, day 288 Respiratory failure; sepsis 
32 Male MVT II Bone Marrow 83 Died, day 247 GVHD of bone marrow 
33 Female MVT II - 30 Died, day 214 Respiratory failure; sepsis 
34 Female MVT II - 24 Alive, day 290 - 
35 Female MVT Unknown - 116 Died, day 156 Acute graft thrombosis 
36 Female MMVT Unknown - 267 Died, day 394 Unknown; alcoholism 
37 Female Intestine Only II - 392 Alive, day 1476 - 
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Table 4. Ratio of donor to recipient (means) based on height, weight, and 
BMI. Analysis by immunologic status. 
      No GVHD  GVHD p-value 
 N=199 N=37  
Donor to recipient size    
Height Ratio 0.99 1.00 0.73 
Weight Ratio 1.00 1.01 0.92 
BMI Ratio 1.00 1.00 0.93 
    
Presence of liver    
Liver inclusive 59% 78% 0.02 
No liver 41% 22%  
    
Panel reactive antibody    
Class I (mean, median) 0, 14 0, 6 0.14 
Class II (mean, median) 0, 11 0, 7 0.44 
    
Crossmatch (flow)    
T-cell positive 16% 8% 0.23 
B-cell positive 17% 11% 0.41 
    
Human leukocyte antigen    
Mismatch number (mean, median) 5,5 4,4 0.06 
    
Any donor specific antibody 19% 11% 0.25 
    
Post-transplant rejection    
Any 36% 14% <0.01 
None 64% 86%  
 
 
